Government Briefs

A Stealth Technology Policy? Critics of the Bush administration's approach to what is nowadays called technology policy - that is, government actions meant to strengthen certain industries deemed essential for the health of the U.S. economy - had a field day during a hearing last month on the subject before the Senate Commerce, Science, and Transportation Committee. The chairman, Sen. Ernest Hollings (D-S.C.), wondered whether a range of such key technologies "will receive government backing or

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A Stealth Technology Policy? Critics of the Bush administration's approach to what is nowadays called technology policy - that is, government actions meant to strengthen certain industries deemed essential for the health of the U.S. economy - had a field day during a hearing last month on the subject before the Senate Commerce, Science, and Transportation Committee. The chairman, Sen. Ernest Hollings (D-S.C.), wondered whether a range of such key technologies "will receive government backing or government indifference." Griffith Resor, president of MRS Technology Inc., a Massachusetts company that makes multimillion-dollar tools for the high-resolution photolithography industry, cracked that "the president's technology policy must be classified because it's one of the best-kept secrets in Washington." In turn, presidential science adviser Allan Bromley defended the administration's actions by saying that the country faces "deep, structural problems" that have to do more with the high cost of capital, the emphasis on short-term ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies